
    
      The trial medication will be administered at 2 dose levels as subcutaneous injections. Each
      patient will receive three injections in total. The trial duration consists of a screening
      period (28 - 2 days prior to the first injection) and a treatment and observation period (4
      months). The trial requires approximately 20 visits at the study site.
    
  